Patent · US Active

Immunogenic composition

US11998579B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Christiane Feron · Rixensart, BE
Sandra Giannini · Rixensart, BE

Key dates

Filing date	Jan 3, 2017
Grant date	Jun 4, 2024
Priority date	—
Expiry date	Mar 14, 2039

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.